This mechanism involves IPP binding to the intracellular domain of the butyrophilin molecule BTN3A1 expressed on cancer cells, which interacts with BTN2A1 to bind and activate the TCR on Vγ9Vδ2 cells [97,98]. The gene discussed is IPP; the disease is cancer.